Semaglutide

📦 Jokainen tilaus on katettuna meidän Reshipment Assurance Policy -politiikkamme piiriin — jos lähetyksesi ei saavu 20 arkipäivässä, lähetämme uuden.

What Is Semaglutide?

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed as a structural analog of the endogenous incretin hormone GLP-1. It is a 31-amino-acid peptide built on the GLP-1(7-37) backbone with three engineered modifications that distinguish it from earlier short-acting analogs: an α-aminoisobutyric acid (Aib) substitution at position 8 that resists DPP-4 cleavage, an arginine substitution at position 34 to prevent off-target acylation, and a C18 fatty diacid attached at lysine 26 via a γ-glutamic acid and two 2-(2-aminoethoxy)ethoxyacetic acid (AEEA) spacers. The fatty-acid tether drives strong reversible binding to circulating albumin, extending the plasma half-life to approximately 165 hours and making semaglutide the longest-acting GLP-1 agonist developed to date for once-weekly subcutaneous dosing in published research.

Semaglutide’s peptide sequence and molecular structure are well-characterised: empirical formula C₁₈₇H₂₉₁N₄₅O₅₉, average molecular weight 4113.58 Da. The compound is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. Pharmaceutical semaglutide is approved by the FDA, EMA, and MHRA under the brand names Ozempic (subcutaneous, type 2 diabetes), Wegovy (subcutaneous, chronic weight management), and Rybelsus (oral, type 2 diabetes). The research-grade semaglutide sold here is vain laboratoriotutkimuskäyttöön and is not FDA-approved for human or veterinary administration. For a deep dive on mechanism, pharmacokinetics, and head-to-head trial data, see our full Retatrutide vs Tirzepatide -opas and the broader tutkimuspeptidien luettelo.

Mechanism of Action — GLP-1 Receptor Signaling Across Three Tissue Compartments

What makes semaglutide more pharmacologically interesting than earlier GLP-1 analogs (liraglutide, exenatide) is the combination of high receptor selectivity with a half-life long enough to maintain near-continuous receptor occupancy. Published research has mapped its activity across three distinct tissue compartments, each contributing to the observed metabolic phenotype:

• Pancreatic β-cell — glucose-dependent insulin secretion — Semaglutide binds the GLP-1 receptor on pancreatic β-cells, activating Gα_s-coupled adenylyl cyclase, raising intracellular cAMP and PKA / EPAC2 signaling. The downstream effect is a glucose-dependent potentiation of insulin secretion: hypoglycaemia is rare because the signal requires elevated intracellular glucose to translate into insulin release. Parallel suppression of glucagon secretion from α-cells contributes to lower fasting hepatic glucose output in diabetes models.
• Central nervous system — appetite and satiety circuits — Semaglutide crosses the blood-brain barrier sufficiently to activate GLP-1 receptors in the arcuate nucleus, paraventricular nucleus, and area postrema. Research in diet-induced obese (DIO) rodent models has documented activation of anorexigenic pro-opiomelanocortin (POMC) neurons and suppression of orexigenic neuropeptide Y / agouti-related peptide (NPY/AgRP) neurons. This central effect is the principal driver of the body-weight phenotype observed in obesity research.
• Gastrointestinal motility — delayed gastric emptying — GLP-1 receptor activation in vagal afferents and enteric neurons slows the rate of gastric emptying, reducing postprandial glucose excursions and prolonging satiety signals. Tachyphylaxis (partial desensitisation) of this effect develops over weeks of continuous receptor occupancy, which is why gastrointestinal tolerability typically improves with prolonged dosing in research models.

The C18 fatty diacid tether is what differentiates semaglutide pharmacokinetically from older GLP-1 analogs. By binding reversibly to serum albumin via this tether, semaglutide forms a circulating depot that protects it from renal clearance and DPP-4 degradation. Combined with the Aib⁸ substitution (which directly blocks the DPP-4 cleavage site at position 8–9), this gives semaglutide a half-life of 165 hours compared with liraglutide’s 13 hours and native GLP-1’s <2 minutes — a roughly 12× extension that enables once-weekly research dosing schedules.

Julkaistut tutkimussovellukset

Semaglutide is used in laboratory research contexts that investigate:

• Glucose homeostasis and insulin sensitivity — glucose-stimulated insulin secretion, oral and intravenous glucose tolerance tests, hyperinsulinaemic-euglycaemic clamps in db/db, ZDF, and high-fat-diet rodent models (Lau et al., J Med Chem 2015; Knudsen & Lau, Front Endocrinol 2019)
• Body weight and appetite regulation — food intake assessments, body composition (DEXA / MRI), respiratory exchange ratio in DIO and ob/ob mouse models; benchmark for novel anti-obesity peptide research
• Cardiovascular and atherosclerosis research — effects on endothelial function, plaque progression in ApoE^-/- and LDLR^-/- mice; mechanistic follow-up to the SUSTAIN-6 and PIONEER cardiovascular signal in clinical trials
• Renal protection and diabetic nephropathy models — albuminuria, glomerulaarinen suodatusnopeus, mesangiaalinen laajentuma streptozotosiini-indusoidussa ja Akita-hiiren diabeteksessa
• Neuroprotection research — cognitive function, neuroinflammation, α-synuclein and amyloid-β pathology in Parkinson’s and Alzheimer’s preclinical models — GLP-1R is expressed throughout the CNS and is a current research frontier
• Hepatic steatosis (MASLD/MASH) research — liver triglyceride content, ALT/AST, fibrosis staging in choline-deficient and high-fat-high-fructose rodent diets
• Comparative metabolic peptide research — benchmarking against newer multi-agonists. See the Retatrutide page for the triple GLP-1/GIP/glucagon comparator and the Retatrutide vs Tirzepatide -opas for a dual-agonist side-by-side.

For broader context on where semaglutide fits within the metabolic-peptide landscape, see our tutkimuspeptidien luettelo and related compounds including Retatrutide (triple agonist) and Tesamorelin (GHRH analog for visceral adiposity research).

Saatavat vahvuudet ja pitoisuudet

MedsBase stocks Semaglutide in seven lyophilized vial strengths to support both micro-dose titration research and extended weekly-dosing protocols. Each strength is available in 10-vial or 20-vial pack formats with full reconstitution guidance:

All seven strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when researchers want to minimise injection volume per administration or run extended multi-month protocols from a single vial.

How It Compares — Semaglutide vs Retatrutide vs Tirzepatide

Semaglutide, Retatrutide, and tirzepatide are the three most-cited long-acting incretin peptides in current metabolic research. They differ primarily in receptor selectivity: semaglutide is a single GLP-1 agonist, tirzepatide is a dual GLP-1/GIP agonist, and retatrutide is a triple GLP-1/GIP/glucagon agonist. The escalating receptor profile correlates with progressively larger body-weight effects in DIO models but also broader off-target signalling.

For a full methodological comparison of the dual- vs triple-agonist research literature, read Retatrutide vs Tirzepatide: kolmoisagonisti vs kaksoisagonisti ja Ozempic vs Mounjaro. Researchers selecting between these peptides typically weigh receptor selectivity (cleaner pharmacology with semaglutide) against magnitude of effect (greater with dual- and triple-agonists).

Säilytys ja liuotus

Ennen liuotusta: store lyophilized vials refrigerated at 2–8 °C in original packaging for short-term working stock. For unopened long-term storage, freeze at −20 °C. Lyophilized semaglutide is stable under refrigeration for up to 24 months and at −20 °C for up to 36 months. Avoid freeze-thaw cycles on the lyophilized powder.

Uudelleenliuotusmenettely: inject bacteriostatic water down the side wall of the peptide vial (not directly onto the lyophilized cake). For a 5 mg vial, 2.0 mL of bacteriostatic water yields a 2.5 mg/mL working concentration — ten units on a U-100 insulin syringe equals 250 mcg. Swirl gently — do ei ravistele — ja anna 2–5 minuuttia täydelliseen liukenemiseen. Oikein uudelleenliuotettu liuos tulisi olla kirkas ja väritön.

Uudelleenliuotuksen jälkeen: store refrigerated at 2–8 °C and use within 30 days for optimal stability. Do not freeze the reconstituted solution — freeze-thaw cycles degrade peptide integrity. Discard any vial showing cloudiness, precipitate, or discolouration. Because semaglutide is dosed once weekly in research protocols, a single reconstituted 5 mg vial typically supports 4–8 weeks of titration research depending on the target dose.

Usein Kysytyt Kysymykset

What is Semaglutide used for in research?

Semaglutide is used in laboratory research investigating glucose homeostasis, insulin secretion, body weight and appetite regulation, gastric emptying, cardiovascular endpoints, renal protection in diabetic nephropathy models, hepatic steatosis (MASLD/MASH), and neuroprotection. It is the most extensively characterised long-acting GLP-1 agonist in the published literature and serves as the benchmark comparator for newer multi-agonist incretin peptides. The research-grade semaglutide sold here is ei FDA:n hyväksymä ihmisten terapian käyttöön ja toimitetaan tiukasti laboratoriotutkimusta varten.

How is Semaglutide different from Retatrutide and Tirzepatide?

The key difference is receptor selectivity. Semaglutide is a single GLP-1 receptor agonist with the cleanest receptor pharmacology of the three. Tirzepatide adds GIP receptor activity (dual agonist). Retatrutide adds glucagon receptor activity on top of that (triple agonist). The escalating receptor profile produces progressively larger body-weight effects in published research but also broader systemic signalling. Semaglutide remains the gold standard for glycaemic control and cardiovascular research; multi-agonists are preferred where maximum body-weight effect is the research endpoint.

What is the typical Semaglutide research dose?

Published preclinical and clinical research protocols typically use a titration schedule starting at 0.25 mg weekly and increasing by 0.25–0.5 mg every 4 weeks up to a maintenance dose of 1.0–2.4 mg weekly. A 5 mg vial reconstituted with 2.0 mL bacteriostatic water yields 2.5 mg/mL — ten units on a U-100 insulin syringe equals 250 mcg.

Is Semaglutide FDA approved?

Pharmaceutical semaglutide is FDA-approved under the brand names Ozempic, Wegovy, and Rybelsus for human therapeutic use in type 2 diabetes and chronic weight management, manufactured to GMP standards by Novo Nordisk. The research-grade semaglutide sold here is a separate product supplied for laboratory research only and is ei ole FDA:n hyväksymä ihmis- tai eläinkäyttöön. Sitä ei saa käyttää ihmisille tai eläimille.

How should Semaglutide be stored?

Lyofiloituja pulloja: lyhytaikainen käyttövarasto jääkaapissa 2–8 °C:ssa tai pitkäaikainen säilytys avaamattomille pulloille −20 °C:ssa. Uudelleenliuotettu liuos: jääkaapissa 2–8 °C:ssa, käytettävä 30 päivän kuluessa. Älä jäädytä uudelleenliuotettua liuosta - jäätymis-lämmitysjaksot heikentävät peptidin laatua. Suojaa aina suoralta valolta.

How do I reconstitute Semaglutide?

Noudata yllä kuvattua uudelleenliuotusmenettelyä. Lisää bakteriostaattista vettä pullon sivuseinää pitkin (ei suoraan lyofiloituun kuoreen), kiertoile hellästi ja anna 2–5 minuuttia täydelliseen liukenemiseen. Älä ei shake the vial. A correctly reconstituted solution is clear and colourless. For a 5 mg vial + 2.0 mL diluent, the working concentration is 2.5 mg/mL.

Mitä vahvuuksia MedsBase pitää varastossaan?

MedsBase carries Semaglutide in seven lyophilized vial strengths: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, and 50 mg. Each strength is available in 10-vial or 20-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request.

What is the half-life of Semaglutide?

Semaglutide has an unusually long plasma half-life of approximately 165 hours (~7 days) following subcutaneous administration. This extended half-life is achieved by reversible binding to circulating serum albumin via the C18 fatty diacid tether at lysine 26, which protects the peptide from renal clearance. The long half-life enables once-weekly dosing schedules in published research, in contrast to native GLP-1 (half-life under 2 minutes) and liraglutide (half-life ~13 hours).

Can Semaglutide and Tirzepatide be compared in research?

Yes — head-to-head comparison is one of the most actively researched areas in metabolic peptide pharmacology. Published trials such as SURPASS-2 (clinical) and a growing body of preclinical work compare the two peptides on glycaemic control, body weight, gastric emptying, and cardiovascular endpoints. Semaglutide is typically the active comparator arm in newer multi-agonist trials because its single-receptor profile provides a clean baseline.

Does Semaglutide cause side effects in research?

The most consistent finding in semaglutide research is gastrointestinal — nausea, transient appetite suppression, and delayed gastric emptying are dose-dependent and tend to attenuate over 4–8 weeks of continuous dosing as receptor tachyphylaxis develops. Less common findings in long-term studies include effects on gallbladder motility and (in rodent models with thyroid C-cell sensitivity) C-cell hyperplasia — the latter is a species-specific signal that has not translated to humans in long-term clinical follow-up.

What is the difference between subcutaneous and oral Semaglutide in research?

Subcutaneous semaglutide (Ozempic, Wegovy) is the standard research route because the peptide is rapidly degraded in the gastrointestinal tract. Oral semaglutide (Rybelsus) is co-formulated with the absorption enhancer SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate), which transiently raises gastric pH and protects the peptide long enough for it to cross the gastric mucosa. Oral bioavailability remains low (~1%), so research-relevant oral doses are substantially higher than subcutaneous equivalents.

How long does Semaglutide take to show effects in preclinical research?

Acute pharmacodynamic effects on glucose tolerance and gastric emptying are detectable within hours of the first dose. Body-weight effects in DIO rodent models typically become statistically significant after 1–2 weeks of weekly dosing and continue to accrue through 8–12 weeks. Maximum effect on body composition is typically observed after 16–20 weeks of continuous dosing in research models.

Can I order Semaglutide for international shipping?

Yes. MedsBase ships Semaglutide worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking and are covered by our Reshipment Assurance Policy -politiikkamme piiriin.

Muut peptidejä aineenvaihdunta- ja kehonkoostumustutkimukseen

• Retatrutide — Triple GLP-1/GIP/glucagon agonist (LY3437943) — the largest body-weight effect in current metabolic peptide research
• Tesamorelin — GHRH analog — visceral adipose tissue and lipodystrophy research
• CJC-1295 DAC:lla — Pitkävaikutteinen GHRH-analoggi kasvuhormoniakselin tutkimukseen
• Ipamorelin — Selective GHRP for clean GH-axis pulse research
• IGF-1 LR3 — Long-arginine IGF-1 analog — anabolic and regenerative research

Lisälukemista

Lisää vaihtoehtoja Peptideissä

Luokiteltu MedsBase-tilausmäärän mukaan — mitä muut asiakkaat tässä kategoriassa valitsevat.

BPC-157

US$115.00 – US$705.00Gama de preços: US$115.00 a US$705.00

Retatrutide

US$310.00 – US$6,515.00Gama de preços: US$310.00 a US$6,515.00

BAC Vesi (Bakteriostaattinen vesi)

US$50.00 – US$150.00Gama de preços: US$50.00 a US$150.00

NAD⁺

US$210.00 – US$1,975.00Gama de preços: US$210.00 a US$1,975.00